BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 37 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,000 | -95.0% | 10,465 | -0.5% | 0.00% | – |
Q1 2021 | $40,000 | 0.0% | 10,516 | +2.4% | 0.00% | – |
Q3 2019 | $40,000 | -2.4% | 10,266 | 0.0% | 0.00% | – |
Q2 2019 | $41,000 | -10.9% | 10,266 | -4.6% | 0.00% | – |
Q1 2019 | $46,000 | +17.9% | 10,766 | 0.0% | 0.00% | – |
Q4 2018 | $39,000 | -4.9% | 10,766 | 0.0% | 0.00% | – |
Q3 2018 | $41,000 | -2.4% | 10,766 | 0.0% | 0.00% | – |
Q2 2018 | $42,000 | +20.0% | 10,766 | 0.0% | 0.00% | – |
Q1 2018 | $35,000 | -16.7% | 10,766 | 0.0% | 0.00% | – |
Q4 2017 | $42,000 | 0.0% | 10,766 | +4.9% | 0.00% | – |
Q3 2017 | $42,000 | -2.3% | 10,266 | 0.0% | 0.00% | – |
Q2 2017 | $43,000 | -6.5% | 10,266 | -4.6% | 0.00% | – |
Q1 2017 | $46,000 | +70.4% | 10,766 | 0.0% | 0.00% | – |
Q4 2016 | $27,000 | +3.8% | 10,766 | 0.0% | 0.00% | – |
Q3 2016 | $26,000 | 0.0% | 10,766 | 0.0% | 0.00% | – |
Q2 2016 | $26,000 | -10.3% | 10,766 | 0.0% | 0.00% | – |
Q1 2016 | $29,000 | -46.3% | 10,766 | -12.2% | 0.00% | -100.0% |
Q1 2015 | $54,000 | +10.2% | 12,266 | +19.5% | 0.00% | 0.0% |
Q4 2014 | $49,000 | – | 10,266 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ABNER HERRMAN & BROCK LLC | 239,000 | $2,679,000 | 0.48% |
EAM Investors, LLC | 81,854 | $918,000 | 0.20% |
CFO4Life Group, LLC | 12,003 | $135,000 | 0.05% |
Phoenix Holdings Ltd. | 104,782 | $1,112,000 | 0.05% |
WINTON GROUP Ltd | 118,487 | $1,328,000 | 0.03% |
Merit Financial Group, LLC | 28,731 | $322,000 | 0.03% |
HighPoint Advisor Group LLC | 13,533 | $151,000 | 0.03% |
SHANDA ASSET MANAGEMENT HOLDINGS Ltd | 23,000 | $258,000 | 0.02% |
ETF MANAGERS GROUP, LLC | 52,216 | $579,000 | 0.02% |
IHT Wealth Management, LLC | 13,000 | $146,000 | 0.02% |